Gilead completes acquisition of MiroBio in $405m cash deal
Gilead Sciences (Gilead) has announced the completion of the previously announced transaction to acquire UK-based biotechnology company MiroBio, for approximately $405m in cash. The deal includes MiroBio’s proprietary discovery platform and its entire portfolio of immune inhibitory receptor agonists.